Ginkgo Bioworks (NYSE:DNA) Stock Sees Heavy Put Option Buying

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) was the target of some unusual options trading on Monday. Traders bought 10,082 put options on the company. This is an increase of 533% compared to the average volume of 1,592 put options.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Reshma Shetty sold 18,803 shares of the business’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $10.14, for a total value of $190,662.42. Following the transaction, the insider directly owned 356,329 shares in the company, valued at $3,613,176.06. The trade was a 5.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Barry Canton sold 22,369 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $10.14, for a total value of $226,821.66. Following the completion of the transaction, the insider directly owned 453,951 shares of the company’s stock, valued at approximately $4,603,063.14. This trade represents a 4.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 136,525 shares of company stock valued at $1,379,699. 12.69% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNA. Balance Capital Partners L.P. bought a new position in Ginkgo Bioworks in the second quarter worth about $1,972,179. Renaissance Technologies LLC purchased a new position in shares of Ginkgo Bioworks in the 1st quarter worth approximately $616,000. Entropy Technologies LP grew its holdings in Ginkgo Bioworks by 374.5% in the third quarter. Entropy Technologies LP now owns 66,279 shares of the company’s stock worth $850,000 after purchasing an additional 52,311 shares during the last quarter. Q Fund Management Hong Kong Ltd purchased a new position in Ginkgo Bioworks in the third quarter worth $505,000. Finally, FORA Capital LLC acquired a new position in shares of Ginkgo Bioworks during the third quarter worth $405,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Ginkgo Bioworks Trading Down 11.2%

Shares of DNA stock traded down $1.07 on Monday, reaching $8.54. The company’s stock had a trading volume of 1,612,374 shares, compared to its average volume of 1,536,313. The stock’s fifty day simple moving average is $10.29 and its 200-day simple moving average is $8.64. Ginkgo Bioworks has a 1 year low of $5.37 and a 1 year high of $18.22. The company has a market capitalization of $574.81 million, a price-to-earnings ratio of -2.05 and a beta of 1.74.

Ginkgo Bioworks (NYSE:DNA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.04. Ginkgo Bioworks had a negative net margin of 249.20% and a negative return on equity of 56.97%. The business had revenue of $27.71 million during the quarter, compared to analyst estimates of $21.50 million.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BTIG Research reaffirmed a “sell” rating and set a $5.00 price objective on shares of Ginkgo Bioworks in a report on Friday, September 4th. Wall Street Zen upgraded shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. TD Cowen raised their target price on shares of Ginkgo Bioworks from $9.00 to $11.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Zacks Research upgraded shares of Ginkgo Bioworks to a “hold” rating in a report on Monday, August 17th. Finally, Oppenheimer set a $5.00 price target on shares of Ginkgo Bioworks in a research note on Wednesday, September 9th. Two analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $7.00.

Get Our Latest Report on DNA

About Ginkgo Bioworks

(Get Free Report)

Ginkgo Bioworks is a biotechnology company that develops and engineers microorganisms and other cells for use in commercial products. Its platform combines biological research, automation, and software to help customers design, build, and test organisms with desired characteristics. The company provides cell-engineering services and capabilities to organizations in areas including pharmaceuticals, agriculture, food, and industrial chemicals. Its work can include developing and optimizing microbial strains and supporting the production of ingredients and other materials.

Featured Stories

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.